|
Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June 2022
SEOUL, South Korea--(BUSINESS WIRE)-- Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for degenerative central nervous system diseases and advanced immuno-oncology therapeutics, announced it will release new preclinical data at two major medical conferences in June.
“We are excited to share new preclinical data for our two drug candidates, SNR1611 and GNUV201,” said Heung-rok Park, Ph.D., chief technology officer of Genuv.
….
To view original article, please click here.
|
